drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Genetically engineered autologous T cells expressing a chimeric antigen receptor targeting CD70 for MHC-independent recognition and killing of CD70-positive tumor cells; administered after lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous, Intraperitoneal
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that specifically binds CD70 on tumor cells, enabling MHC-independent recognition. CAR signaling (CD3ΞΆ with costimulation) activates the T cells to proliferate, release cytokines, and deliver cytotoxic killing of CD70-positive tumor cells. Lymphodepletion prior to infusion enhances CAR-T expansion and persistence.
drug_name
CD70 CAR-T cells
nct_id_drug_ref
NCT06010875